Skip to main content

Table 5 Association between cardiovascular comorbidities and the use of Methotrexate and Leflunomide

From: Cardiovascular risk comorbidities in rheumatoid arthritis patients and the use of anti-rheumatic drugs: a cross-sectional real-life study

  Methotrexate Leflunomide
Yes n*(%) PRˆ (IC95%) p Yes n*(%) PRˆ (IC95%) p
Cardiovascular Comorbidities Yes 463 (62.4) 0.945 (0.862–1.036) 0.232 251 (66.4) 1.068 (0.975–1.170) 0.167
No 279 (37.6) 1.107 (0.935–1.311) 127 (33.6) 0.889 (0.750–1.053)
Systemic Arterial Hypertension Yes 365 (49.2) 0.958 (0.847–1.083) 0.499 195 (51.6) 1.052 (0.931–1.188) 0.423
No 377 (50.8) 1.044 (0.921–1.184) 183 (48.4) 0.950 (0.838–1.078)
Dyslipidemia Yes 236 (31.8) 0.937 (0.785–1.117) 0.469 129 (34.1) 1.076 (0.903–1.283) 0.414
No 506 (68.2) 1.033 (0.946–1.127) 249 (65.9) 0.965 (0.884–1.053)
Diabetes Mellitus Yes 111 (15) 1.017 (0.755–1.371) 0.910 52 (13.8) 0.891 (0.657–1.207) 0.453
No 631 (85) 0.997 (0.947–1.050) 326 (86.2) 1.020 (0.970–1.073)
Congestive Heart Failure Yes 18 (2.4) 1.512 (0.605–3.777) 0.372 7 (1.9) 0.804 (0.336–1.922) 0.623
No 724 (97.6) 0.992 (0.975–1.009) 371 (98.1) 1.005 (0.987–1.023)
Cerebrovascular Disease Yes 14 (1.9) 0.706 (0.316–1.574) 0.392 9 (2.4) 1.171 (0.517–2.652) 0.704
No 728 (98.1) 1.008 (0.989–1.028) 369 (97.6) 0.996 (0.978–1.015)
Acute Myocardial Infarction Yes 12 (1.6) 1.210 (0.429–3.408) 0.718 3 (0.8) 0.418 (0.121–1.447) 0.200
No 730 (98.4) 0.997 (0.982–1.012) 375 (99.2) 1.011 (0.998–1.025)
Peripheral Vascular Disease Yes 5 (0.7) 0.840 (0.202–3.496) 1.000 5 (1.3) 3.254 (0.782–13.543) 0.129
No 737 (99.3) 1.001 (0.990–1.012) 373 (98.7) 0.991 (0.970–1.003)
  1. *Absolute frequencies; ˆ Prevalence Ratio Significance level